Acromegaly Combination Treatment Study

Summary

Acromegaly Combination Treatment Study is a clinical trial^[1].

Key Facts

• Acromegaly Combination Treatment Study is in the country of United States^[2].
• Acromegaly Combination Treatment Study's instance of is recorded as clinical trial^[3].
• Acromegaly Combination Treatment Study's start time is recorded as +2012-01-31T00:00:00Z^[4].
• Acromegaly Combination Treatment Study's end time is recorded as +2020-03-31T00:00:00Z^[5].
• Acromegaly Combination Treatment Study's sponsor is recorded as Cedars-Sinai Medical Center^[6].
• Acromegaly Combination Treatment Study's main subject is recorded as acromegaly^[7].
• Acromegaly Combination Treatment Study's number of participants is recorded as {'unit': '1', 'amount': '+51'}^[8].
• Acromegaly Combination Treatment Study's title is recorded as Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy and High-Dose SRL + Weekly Pegvisomant Therapy^[9].
• Acromegaly Combination Treatment Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Acromegaly Combination Treatment Study's ClinicalTrials.gov ID is recorded as NCT01538966^[11].
• Acromegaly Combination Treatment Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+85'}^[12].
• Acromegaly Combination Treatment Study's research intervention is recorded as octreotide^[13].
• Acromegaly Combination Treatment Study's research intervention is recorded as lanreotide^[14].
• Acromegaly Combination Treatment Study's research site is recorded as Cedars-Sinai Medical Center^[15].
• Acromegaly Combination Treatment Study's research subject recruitment status is recorded as recruiting^[16].
• Acromegaly Combination Treatment Study's study type is recorded as interventional study^[17].